222639-98-7Relevant articles and documents
C-2 derivatized 8-sulfonamidoquinolines as antibacterial compounds
Davison, Emma K.,McGowan, John E.,Li, Freda F.,Harper, Andrew D.,Jeong, Joo Young,Mros, Sonya,Harbison-Price, Nichaela,Van Zuylen, Essie M.,Knottenbelt, Melanie K.,Heikal, Adam,Ferguson, Scott A.,McConnell, Michelle A.,Cook, Gregory M.,Krittaphol, Woravimol,Walker, Greg F.,Brimble, Margaret A.,Rennison, David
supporting information, (2020/11/25)
A series of C-2 derivatized 8-sulfonamidoquinolines were evaluated for their antibacterial activity against the common mastitis causative pathogens Streptococcus uberis, Staphylococcus aureus and Escherichia coli, both in the presence and absence of supplementary zinc (50 μM ZnSO4). The vast majority of compounds tested were demonstrated to be significantly more active against S. uberis when in the presence of supplementary zinc (MICs as low as 0.125 μg/mL were observed in the presence of 50 μM ZnSO4). Compounds 5, 34–36, 39, 58, 79, 82, 94 and 95 were shown to display the greatest antibacterial activity against S. aureus (MIC ≤ 8 μg/mL; both in the presence and absence of supplementary zinc), while compounds 56, 58 and 66 were demonstrated to also exhibit activity against E. coli (MIC ≤ 16 μg/mL; under all conditions). Compounds 56, 58 and 66 were subsequently confirmed to be bactericidal against all three mastitis pathogens studied, with MBCs (≥3log10 CFU/mL reduction) of ≤ 32 μg/mL (in both the presence and absence of 50 μM ZnSO4). To validate the sanitizing activity of compounds 56, 58 and 66, a quantitative suspension disinfection (sanitizer) test was performed. Sanitizing activity (>5log10 CFU/mL reduction in 5 min) was observed against both S. uberis and E. coli at compound concentrations as low as 1 mg/mL (compounds 56, 58 and 66), and against S. aureus at 1 mg/mL (compound 58); thereby validating the potential of compounds 56, 58 and 66 to function as topical sanitizers designed explicitly for use in non-human applications.
QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS
-
Page/Page column 68; 73, (2019/07/13)
The invention provides novel quinoline sulfonamide compounds of Formula I: (Formula (I)) and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, infections caused by one or more bacteria from the Enterobactericeae, Staphylococcaceae, or Streptococcaceae families. The compounds described and claimed herein may be formulated in one or more pharmaceutical or veterinary compositions for use in animal husbandry, and in particular in relation to the treatment of mastitis by directly targeting mastitis causing bacteria in a bovine herd. In certain embodiments described herein the pharmaceutical or veterinary compositions are formulated as a spray for direct administration to the udder of the bovine animal such as a cow.
BENZOIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING THE SAME
-
Page/Page column 80, (2010/04/03)
Benzoimidazole Derivatives are provided. The compounds of the present invention are useful for Glycogen Synthase Kinase-3 Beta Inhibitors.
P'-Extended α-ketoamide inhibitors of proteasome
Chatterjee, Sankar,Dunn, Derek,Mallya, Satish,Ator, Mark A.
, p. 2603 - 2606 (2007/10/03)
A series of potent P'-extended α-ketoamide inhibitors of chymotrypsin-like activity of proteasome is described.
